Publication
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerMelanomacivic_curation1.00
- drugSorafenibcivic_curation1.00
- drugVemurafenibcivic_curation1.00
- geneBRAFcivic_curation1.00
- variantBRAF Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23890088
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF Fusion2 | ||||||||
| Sorafenib | Melanoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID723BRAF fusion AGK-BRAF was associated with decreased sensitivity to vemurafenib and increased sensitivity to sorafenib in-vitro. A single patient with this fusion showed durable response to sorafenib. PMID 23890088 · Botton et al., 2013 · Open in CIViC | civic |
| Vemurafenib | Melanoma | Predictive | D | Supports Resistance | 2 | accepted | EID724A melanoma cell line with AGK-BRAF in-frame fusion showed decreased sensitivity towards Vemurafenib in comparison with BRAF mutated (V600E) cell lines. PMID 23890088 · Botton et al., 2013 · Open in CIViC | civic |